Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma.
Brian I RiniSabina SignorettiToni K ChoueiriDavid F McDermottRobert J MotzerSaby GeorgeThomas PowlesFrede DonskovScott S TykodiSumanta Kumar PalSaurabh GuptaChung-Wei LeeRuiyun JiangNizar M TannirPublished in: Journal for immunotherapy of cancer (2022)
NCT02231749.